Chembio Diagnostics Completes Public Offering

Chembio Diagnostic develops, manufactures and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. All products that are currently being developed are based on the company’s patented DPP® technology, which is a novel point-of-care diagnostic platform that offers certain customer advantages, as compared to traditional lateral flow technology. Our firm represented Craig-Hallum Capital Group LLC as the sole underwriter for the $12 million offering.